|
|
|
|
|
|
|
heaval may even be a healthy wake-up call for the industry. What is dangerous, however, is the current interregnum of uncertainty with clinical testing cut back until companies get a better understanding of the reforms currently being considered by Congress. It is not the change that damages, it is the uncertainty and the absence of clear decisions. Those companies that fail to make these choices soon will surely fail. |
|
|
|
|
|